First‐in‐human study of blood amyloid β removal from early Alzheimer's disease patients with normal kidney function

Amyloid β (Aβ) is a brain protein that causes Alzheimer's disease (AD). This study aimed to verify whether hemadsorption using a hexadecyl-alkylated cellulose bead (HexDC) column removes blood Aβ and brain Aβ accumulation in mild cognitive impairment/mild AD cases with normal kidney function.Two patients with positive Aβ on brain imaging underwent HexDC hemadsorption weekly for 6 months.The Aβ removal efficiency of HexDC was 87-99%. AβBlood Aβ removal was performed in two early AD patients with normal kidney function without adverse events, and it slightly improved or maintained cognitive function.